Trabectedin-Olaparib Combination Shows Promise for Advanced Soft Tissue Sarcoma Subgroups
核心洞察
A phase 2 randomized trial of 130 patients found that trabectedin plus olaparib achieved a 32% six-month progression-free survival rate compared to 28% with trabectedin alone in advanced soft tissue sarcoma.
The combination showed particular benefit in patients with PARP1 (搜索) expression and uterine leiomyosarcoma, with 40% of uterine leiomyosarcoma patients remaining progression-free at 12 months.
While the overall benefit was marginal in the all-comers population, the study identified PARP1 (搜索) expression as a promising biomarker for selecting patients who may benefit from this combination therapy.
A phase 2 randomized trial has demonstrated that combining trabectedin with the PARP inhibitor olaparib may offer meaningful treatment benefits for specific subgroups of patients with advanced soft tissue sarcoma (STS), according to research published in the Annals of Oncology.
The study, led by Giovanni Grignani, MD, of Italy's Candiolo Cancer Institute (搜索), enrolled 130 adult patients with advanced STS who had progressed after at least one anthracycline-based therapy. Patients were randomized 1:1 to receive either intravenous trabectedin at 1.1 mg/m² every 21 days plus 150 mg olaparib tablets twice daily, or trabectedin alone at 1.5 mg/m² every 21 days.
Primary Efficacy Results
At a median follow-up of 37.4 months, the combination therapy achieved a six-month progression-free survival (PFS) rate of 32% (95% CI, 22%-46%) compared to 28% (95% CI, 19%-42%) with trabectedin alone. Median PFS was 3.9 months (95% CI, 2.7-5.2) in the combination group versus 2.9 months (95% CI, 2.2-3.6) in the trabectedin-only group.
While the combination reached its prespecified significance threshold (P < 0.10), the researchers noted that the benefit was marginal in the overall patient population. The overall response rate was 12.7% in the combination group compared to 7.9% with trabectedin alone.
Promising Subgroup Benefits
The study revealed more substantial benefits in specific patient subgroups. Patients with PARP1 (搜索) expression in their tumor tissue showed significantly improved PFS with combination therapy. Most notably, 40% of patients with uterine leiomyosarcoma (uLMS) remained progression-free at 12 months.
The patient population included 81 females, with 93 patients having received one prior line of therapy. Sixty-seven patients had either liposarcoma or leiomyosarcoma, while the remainder had non-L-STS.
Safety Profile
Grade 3 or higher hematological toxicities occurred more frequently in the combination group compared to trabectedin alone, though specific rates were not detailed in the study.
Mechanistic Rationale
The combination strategy builds on trabectedin's mechanism of action, which involves binding to DNA (搜索)'s minor groove and interfering with DNA damage response and repair machinery. This creates DNA single- and double-strand breaks while exerting selective toxicity on tumor-associated macrophages involved in tumor angiogenesis and progression.
The researchers hypothesized that PARP1 (搜索) inhibitors might work synergistically with trabectedin, as the DNA (搜索) damage caused by trabectedin activates PARP1. A 2017 preclinical study by the same team confirmed this hypothesis, showing that combining trabectedin with olaparib increased apoptotic rates in vitro and reduced tumor growth while preventing metastatic spread in animal models.
Clinical Implications
The investigators concluded that uterine leiomyosarcoma appears to be the most promising cancer type for further evaluation of PARP1 (搜索) inhibition combined with chemotherapy. They identified PARP1 expression as a promising biomarker for patient selection.
"Finally, improving the assessment of DDRR defects in STS could provide valuable insights and guide more effective therapeutic approaches," the researchers concluded, suggesting that better understanding of DNA (搜索) damage response and repair defects in soft tissue sarcomas could lead to more targeted treatment strategies.